Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3815126
Max Phase: Preclinical
Molecular Formula: C32H41N5O7
Molecular Weight: 607.71
Molecule Type: Small molecule
Associated Items:
ID: ALA3815126
Max Phase: Preclinical
Molecular Formula: C32H41N5O7
Molecular Weight: 607.71
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@@H]1[C@@H](c2ccccc2)CCN1C(=O)[C@@H](NC(=O)c1cc(C)on1)C(C)C
Standard InChI: InChI=1S/C32H41N5O7/c1-5-43-26(38)12-11-23(18-22-13-15-33-29(22)39)34-31(41)28-24(21-9-7-6-8-10-21)14-16-37(28)32(42)27(19(2)3)35-30(40)25-17-20(4)44-36-25/h6-12,17,19,22-24,27-28H,5,13-16,18H2,1-4H3,(H,33,39)(H,34,41)(H,35,40)/b12-11+/t22-,23+,24+,27-,28-/m0/s1
Standard InChI Key: RDIZZIQRWFVOSX-SCALXIMVSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 607.71 | Molecular Weight (Monoisotopic): 607.3006 | AlogP: 2.25 | #Rotatable Bonds: 12 |
Polar Surface Area: 159.94 | Molecular Species: NEUTRAL | HBA: 8 | HBD: 3 |
#RO5 Violations: 1 | HBA (Lipinski): 12 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: 12.47 | CX Basic pKa: | CX LogP: 2.03 | CX LogD: 2.03 |
Aromatic Rings: 2 | Heavy Atoms: 44 | QED Weighted: 0.24 | Np Likeness Score: -0.25 |
1. Kawatkar SP, Gagnon M, Hoesch V, Tiong-Yip C, Johnson K, Ek M, Nilsson E, Lister T, Olsson L, Patel J, Yu Q.. (2016) Design and structure-activity relationships of novel inhibitors of human rhinovirus 3C protease., 26 (14): [PMID:27265257] [10.1016/j.bmcl.2016.05.066] |
Source(1):